Loading...
XETR
FME
Market cap13bUSD
Dec 04, Last price  
40.10EUR
1D
-0.59%
1Q
-4.50%
Jan 2017
-50.16%
Name

Fresenius Medical Care AG & Co KGaA

Chart & Performance

D1W1MN
XETR:FME chart
P/E
21.87
P/S
0.61
EPS
1.83
Div Yield, %
2.97%
Shrs. gr., 5y
14.15%
Rev. gr., 5y
2.04%
Revenues
19.34b
-0.61%
5,717,514,4996,439,636,1026,666,871,7637,623,256,1037,850,289,0469,063,019,1319,872,028,54310,434,945,23110,580,072,09813,019,603,52015,309,579,08017,030,495,24017,784,000,00016,547,000,00017,477,000,00017,859,000,00017,619,000,00019,398,000,00019,453,617,00019,335,909,000
Net income
538m
+7.80%
384,120,523406,687,076491,857,953587,319,812621,978,678735,746,932826,448,868897,393,757803,760,140859,366,200941,185,1401,181,894,1201,280,000,0001,982,000,0001,200,000,0001,164,377,000969,308,000673,405,000498,997,000537,913,000
CFO
2.39b
-9.23%
565,944,370687,853,712822,751,819730,119,339934,568,4401,028,693,1871,115,661,3001,541,817,0961,473,565,0841,530,411,9601,792,733,6002,034,797,6002,192,000,0002,062,000,0002,567,000,0004,233,000,0002,489,000,0002,167,000,0002,628,801,0002,386,144,000
Dividend
May 23, 20250 EUR/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
IPO date
Oct 02, 1996
Employees
124,295
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT